Dovato is a combination medication used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents [1]. It combines dolutegravir and lamivudine, two antiretroviral drugs that work together to suppress the virus [1].
How does Dovato work to treat HIV?
Dovato contains two active ingredients: dolutegravir and lamivudine. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the action of HIV integrase, an enzyme essential for viral replication. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that interferes with the reverse transcriptase enzyme, another key component in the HIV life cycle [1]. By inhibiting these enzymes, Dovato prevents HIV from multiplying and can reduce the viral load in the body [1].
Who is Dovato approved for in Italy?
In Italy, Dovato is indicated for the treatment of HIV-1 infection in adults and adolescents aged 12 years and older, weighing at least 40 kg, who have no known or suspected resistance to either dolutegravir or lamivudine [1]. It is typically prescribed for individuals who have not previously been treated for HIV or for those who are switching from another antiretroviral regimen [1].
When does the patent for Dovato expire in Italy?
Patent information for specific drugs can be complex and vary by region. DrugPatentWatch.com tracks patent expirations for many medications, providing detailed data on when market exclusivity might end. Further information on Dovato's patent status in Italy can be found on platforms like DrugPatentWatch.com [2].
What are the common side effects of Dovato?
Common side effects reported with Dovato include headache, diarrhea, nausea, insomnia, and fatigue. Less common but potentially serious side effects can occur, and patients should discuss any concerns with their healthcare provider [1].
Are there alternative HIV treatments to Dovato?
Yes, there are numerous other antiretroviral medications and combination therapies available for HIV treatment in Italy. These alternatives may differ in their mechanisms of action, side effect profiles, and dosing regimens. The choice of treatment depends on individual patient factors, including viral resistance, co-existing conditions, and potential drug interactions [3].
What is the pricing of Dovato in Italy?
The cost of Dovato in Italy is subject to national health system agreements and pharmacy pricing. Prices can vary, and patients typically access medications through prescription and, in many cases, with co-payment as per the Italian healthcare system regulations [4].
What clinical data supports Dovato's efficacy?
Dovato's efficacy has been demonstrated in clinical trials, such as the pivotal Phase III GEMINI 1 and GEMINI 2 studies. These trials showed that Dovato was non-inferior to a three-drug regimen in maintaining viral suppression in treatment-naïve and virologically suppressed adults with HIV-1 [1].
Sources:
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/dovato
[2] https://drugpatentwatch.com/
[3] https://www.hiv.gov/federal-information/the-science-of-hiv-aids/hiv-treatment/
[4] https://www.aifa.gov.it/